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ABSTRACT: We report experimental studies on the development of photoactivatable fluorophores for rapid, light-induced synthesis 
of protein-conjugates. Proof-of-concept studies demonstrated that electronic excitation of photoactivatable BODIPY-ArN3 (1) in the 
presence of different proteins leads to efficient labelling in less than 10 minutes. After synthesis and isolation of the fluorescently-
tagged protein, photochemical conversion yields (PCCs) using human serum albumin (HSA) and onartuzumab (MetMAbTM) were 47 
± 7%, and 42 ± 5%, respectively. 
Fluorescent protein-conjugates are vital tools in chemical and 
biomedical research. For instance, fluorescently-tagged anti-
bodies (mAbs) are used in a wide range of applications, includ-
ing substrate staining in gel-based assays, biomarker detection 
in tissue sections using immunohistochemistry and  confocal 
fluorescence microscopy, cellular labelling in fluorescence as-
sisted cell-sorting (FACS) and molecular imaging in vivo using 
fluorescence-mediated tomography (FMT).1 Although inher-
ently fluorescent proteins, such as green fluorescent protein 
(GFP), can be used for imaging, extrinsic labelling of non-emis-
sive proteins with organic fluorophores provides access to a 
more diverse set of tools with control over their biological func-
tion and optical properties.2–4 
Many organic small-molecule fluorophores have been em-
ployed for fluorescence-based detection methods. Commonly 
used dyes include the cyanine, fluorescein, rhodamine and 
BODIPY families.5,6 The 4,4-difluoro-4-bora-3a,4a-diaza-s-in-
dacene (BODIPY) scaffold offers several advantages for use in 
biological systems, including vivid chromophores, good fluo-
rescence quantum yields, and high stability at physiological 
pH.7 Auxochromic modifications can also be introduced to the 
BODIPY scaffold, thereby allowing the characteristic absorp-
tion and emission bands to be modulated to the more biologi-
cally suitable near infrared (NIR) region. For instance, the ad-
dition of thienyl groups on the pyrrole ring induces a batho-
chromic shift.8,9  
Established methods for labelling biologically active mole-
cules with derivatives of BODIPY (or other fluorophores) are 
usually based on thermochemically initiated reactions, 
including modification of lysine residues with N-hydroxy-
succinimide (NHS) and isothiocyanate (NCS)-activated 
BODIPY agents, cysteine-specific functionalization with ma-
leimide-BODIPY, and copper-mediated ‘click’ chemistry with 
alkyne- or azide-functionalized BODIPY.10–16 Reactions at cys-
teine residues often require the addition of a reducing agent to 
break disulfide bridges and reveal the reactive sulfhydryl 
groups. Although the ‘click’ approach is reliable and efficient, 
it requires multi-step chemistry involving  pre-modification of 
the protein with either an alkyne or azide group, followed by 
bioorthogonal protein-functionalization with the fluoro-
phore.17,18 Both Michael addition to sulfhydryl groups and cop-
per-mediated ‘click’ reactions require the use of potentially 
harsh, redox-active chemicals for the bioconjugation step 
(TCEP, DTT, THTPA, CuSO4), which has the potential to com-
promise the biological integrity and function of the protein by 
disrupting the tertiary structure.10,12 To expand the scope of flu-
orescently labelled biomolecules, alternative strategies for tag-
ging proteins are required. Ideally, new methods should be sim-
ple, efficient and reproducible, allowing for the rapid, one-step 
labelling of unmodified proteins with minimal intervention. 
Here, we report a new method to incorporate the BODIPY scaf-
fold into biomolecules as another method to complement the 
existing toolbox of inherently and tagged fluorescent proteins.  
Photochemistry offers a range of reagents and mechanisms 
with potential for use in light-induced protein-functionalization. 
For example, in 2015, Murale et al. reported the synthesis of an 
asymmetric photoactivatable BODIPY bearing a modified ben-
zophenone motif attached to the 2- or 3-position of one of the 
 
pyridyl groups.19 Excitation of the aryl ketone likely produces a 
triplet biradical species, which was reported to allow photo-in-
duced labelling of three different proteins, including HSA, bo-
vine serum albumin (BSA) and lysozyme under UV irradiation. 
Although promising, the approach has several drawbacks. Spe-
cifically, photo-induced reactions gave very low efficiencies 
(typically 0.1 – 0.6%; with a maximum of 3.5% with tyrosine) 
and protein labelling yields were not reported, and photoexcita-
tion required the use of UV light at wavelengths that are likely 
to damage the protein. To circumvent these issues, we report 
the synthesis of BODIPY-ArN3, in which the aryl azide (ArN3) 
group is distal to the BODIPY chromophore and is photoacti-
vated at wavelengths (365 nm) that are not absorbed by most 
proteins, thereby avoiding detrimental photodegradation.  
BODIPY-ArN3 (1) was synthesized in 4-steps starting from 
4-hydroxybenzaldehyde and isolated with an overall yield of 
22% (Scheme 1; Supporting Figures 1–14).20 The ArN3 group 
was installed in the final step by amide coupling with 4-az-
idoaniline hydrochloride in a yield of 62%. The single-crystal 
X-ray structure of compound 1 was also obtained (Figure 1 and 
Supporting Table 4). Full experimental details and characteri-
zation data including 1H, 19F and 13C NMR, high-resolution 
mass spectrometry, electronic absorption (UV/vis) spectros-
copy, fluorescence spectroscopy and X-ray crystallography 




Scheme 1. Synthesis of BODIPY-ArN3 (1). (i) acetic anhydride, cat. TFA, 2,4-dimethylpyrrole, DCM; (ii) DDQ, DCM/THF; (iii) 





Figure 1. Single-crystal X-ray structure of BODIPY-ArN3 




Figure 2. Electronic absorption (UV/vis) profile of (blue) 
BODIPY-ArN3 (1) and (red) BODIPY-azepin-MetMAb. 
 
The maximum excitation and emission wavelengths of com-
pound 1 were determined to be 497.5 nm and 508.5 nm, respec-
tively (Supporting Figure 12). The small Stokes shift (~11 nm) 
is characteristic of BODIPY compounds, which undergo little 
change in geometry upon photoexcitation.21,22 The quantum 
yield of compound 1 (Φ) was determined in 0.1 M NaOH rela-
tive to fluorescein and found to be 0.03 (Supporting Figure 13) 
which is within the wide range of previously reported quantum 
yields for BODIPY compounds.23–26 The electronic absorption 
profile of compound 1 showed an intense band at the wave-
length used for photo-activation, 365 nm (e = 10,500 M-1 cm-1; 
Figure 2; Supporting Figure 14 and Supporting Tables 1 and 2).  
Light-induced activation of the para-substituted ArN3 group 
initially leads to the formation a highly reactive open-shell sin-
glet nitrene species after loss of N2(g).
27 The reactivity of aryl 
nitrenes is well-established.28 It has a reported half-life on the 
order of a nanosecond and can react via several pathways, in-
cluding H-atom abstraction, (C-H or X-H) bond insertion or in-
tramolecular rearrangements to form a 7-membered ketenimine 
ring. This ketenimine species reacts readily with nucleophiles 
(including the e-NH2 group of lysine) in a bimolecular reaction 
to form an azepine linkage between the protein and the lig-
and.29–32 Although productive bimolecular reactions with pri-
mary amine groups of proteins appears to be favoured kinet-
ically, the ketenimine intermediate can also reactions slowly 
with other nucleophiles, including nonproductive quenching 
with water.27,33 Density functional theory (DFT) calculations 
were performed to investigate the mechanism and photochemi-
cal reaction coordinate of compound 1 (Supporting Table 3 and 
Supporting Figures 15–17). The DFT calculations revealed that 
rearrangement of the open-shell singlet nitrene (1A2 state) to 
give the ketenimine is feasible and subsequent nucleophilic at-
tack by primary amines is thermodynamically favored com-
pared with attack by carboxylate groups.  
Before testing protein-conjugation reactions, the photochem-
ical reactivity of BODIPY-ArN3 (1) was studied by using high-
 
performance liquid chromatography (HPLC). A solution of 
compound 1 (0.25 mM, in MeOH) was irradiated by using a 
high-powered light-emitting diode (LED, 365 nm; 263 mW) at 
room temperature. Aliquots of the photolysis reaction were an-
alyzed by HPLC at time points from 0 to 5 min. (Figure 3A). 
As a control, the intermediate compound, BODIPY-OEt (3), 
which lacks the ArN3 group, was also irradiated under equiva-
lent conditions to determine if the BODIPY core was suscepti-
ble to photodegradation at 365 nm (Figure 3B). HPLC analysis 
indicated that after 4 minutes, compound 1 reacted completely 
to give one major species, which was more polar than the start-
ing material. Intermediate 3 produced only minor impurities af-
ter 5 minutes of irradiation, which indicated that the BODIPY 
scaffold is stable to the irradiation conditions and that the light-
induced reactivity of compound 1 is mediated by the ArN3 
group. Mass spectrometry data from the photolysed product 
were consistent with the loss of N2 and the formation of an aze-
pine or related isomer (Supporting Figures 18 and 19). 
 
Figure 3. HPLC chromatograms showing photodegradation 









Next, we performed a series of experiments to determine if 
light-induced activation of BODIPY-ArN3 (1) in the presence 
of protein could lead to the formation of fluorescent protein-
conjugates. Two different proteins were studied: HSA and the 
humanized, monovalent engineered antibody onartuzumab (for-
mulated as the pharmaceutical MetMAbTM), which targets the 
human hepatocyte growth-factor receptor c-MET (Scheme 2).  
Aliquots of BODIPY-ArN3 (1, DMSO) were added to stock 
solutions of HSA (reconstituted in sterile saline; 69.08 kDa, 60 
Lys, ε280 = 36,500 M
-1 cm-1) or MetMAbTM (containing the na-
tive formulation buffer; 99.16 kDa, 66 Lys, ε280 = 161,465 M
-1 
cm-1).34 The pH of the protein solution was adjusted to 8.0-8.5 
by using aliquots of Na2CO3. Solutions were mixed thoroughly 
before irradiation at 365 nm for 10 min at room temperature. 
Full experimental details are presented in the Supporting Infor-
mation. After irradiation, proteins were purified from the small-
molecule components by size-exclusion chromatography (SEC) 
using PD-10 columns eluted with PBS buffer (pH7.4) (Support-
ing Figure 20). Purified proteins were collected in the high mo-
lecular weight fraction and analyzed by electronic absorption 
spectroscopy (Figure 2 (red)), gel electrophoresis (Figure 4 and 
Supporting Figures 21 and 22) and by using SEC coupled to 
HPLC (Supporting Figure 23). HPLC analysis and visual anal-
ysis confirmed that the protein-fraction (detected at l = 280 nm) 
co-eluted with a peak observed in the 515 nm channel, which 
was assigned to the absorption of the BODIPY dye. However, 
to determine whether the dye was covalently bound to the pro-
tein and to exclude the possibility that the photo-BODIPY-ArN3 
was forming aggregates (or polymers) during irradiation that 
co-elute with the protein fraction, a control reaction where com-
pound 1 was irradiated in the absence of protein was performed. 
After irradiation, the reaction products were purified by PD-10 
SEC and the fractions analyzed by fluorescence emission inten-
sity. Analysis of the high molecular weight fraction from con-
trol reactions showed <8% of the total fluorescence intensity 
found in the protein-conjugation reactions with MetMAbTM 
(Supporting Figure 19). These data confirmed that light-in-
duced activation of BODIPY-ArN3 in the presence of protein 
leads to specific protein functionalization. 
 
Figure 4. SDS Page analysis of (A) Unmodified MetMAb, 
(B) BODIPY-azepin-MetMAb analyzed by (left) fluorescence 
imaging showing pseudo-colored bands and (right) Coomassie 
staining.  
 
Further confirmation of protein-conjugation was obtained by 
running samples of unfunctionalised MetMAbTM, and photo-
conjugated BODIPY-azepin-MetMAb on SDS-PAGE in non-
reducing conditions (Figure 4). Gels were first visualized by 
fluorescence imaging, followed by incubation with Coomassie 
to stain protein bands. Coomassie-stained gels showed one band 
for MetMabTM at approximately 100 kDa, which corresponds 
with the intact one-arm antibody (Figure 4, right lanes A and 
B). Fluorescent imaging showed a band that migrated to the 
 
same position but corresponded with BODIPY-azepin-
MetMAb (Figure 4, left lane B). Gel-electrophoresis of 
BODIPY-azepin-HSA and BODIPY-azepin-MetMAb run un-
der reducing conditions are shown in Supporting Figures 20 and 
21, respectively. The reducing SDS-PAGE of BODIPY-azepin-
MetMAb showed that both the light-chain and the heavy-chain 
are fluorescently labelled. Notably, under the conditions used 
for the gel-electrophoresis, non-covalently bound dye mole-
cules are highly unlikely to remain bound to the protein. 
After confirming the successful protein-conjugation, we next 
evaluated the photochemical conjugation efficiency (PCC; or 
yield) and the degree of labelling (D.O.L) by using different 
stoichiometric equivalents of compound 1 (Table 1). To avoid 
precipitation of the protein and to ensure that the DMSO content 
remained <10%, reactions using 10 equivalents of compound 1 
were performed at lower protein concentrations.  The D.O.L. 
was calculated from calibrated UV/vis spectra of the purified 
protein-conjugates by using Equation 1. From the experimental 
D.O.L, the yield could be calculated by division with the theo-
retical maximum yield. 
𝐷. 𝑂. 𝐿 = 	
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Table 1. Degree of labelling and photochemical conversion yields for the light-induced protein-conjugation reaction BODIPY-
ArN3 (1) with MetMAb
TM and HSA versus varying equivalents of compound 1. 
Protein [protein] 
(µM) 
Equivalents of 1 D.O.L. 
average ± s.d (n = 3) 
PCC  
yield ± s.d (%) (n = 3) 
MetMAb 168 2.5 0.82 ± 0.07 33 ± 3 
 168 5 2.21 ± 0.24 42 ± 5 
 101 10 4.06 ± 0.34 41 ± 3 
HSA 208 2.5 1.17± 0.18 47±7 
 195 4.8 1.62 ± 0.28 34 ± 6 
 96 10 1.84 ± 0.44 28 ± 4 
Photochemical conversion efficiencies did not reach quanti-
tative yields since other competing reactions exist. It has been 
reported that the ketenimine species can react slowly with water 
and O2.
32,33 It is possible that reactive nucleophiles (i.e. histi-
dine) present in the formulation buffer of MetMAbTM compete 
with lysine groups on the protein. In addition to intramolecular 
rearrangement to the ketenimine, the aryl nitrene species pro-
duced after photo-induced loss of N2 can undergo intersystem 
crossing to give a triplet species or protonation to form a 
nitrenium ion which is unreactive towards amino acids.28 
Photochemical conjugation to MetMAb and HSA proceeded 
efficiently with slightly varying yields that were dependent on 
the initial equivalents of BODIPY-ArN3 added. The PCC was 
calculated as the average (n = 3) ± the standard deviation (s.d.). 
HSA was labelled the most efficiently with 2.5 eq. of compound 
1 (PCC = 47±7%). MetMAbTM could be labelled slightly more 
efficiently with a larger initial excess of compound 1 (5-10 
equivalents). Our previous studies involving immunoreactivity 
measurements indicated that irradiation of MetMAbTM at 365 
nm does not compromise protein function.32 
Light-induced protein-conjugation offers several advantages 
over existing coupling methods. First, reactions are extremely 
fast and run to completion in just a few minutes. Increased irra-
diation flux can also reduce reaction times.31 Functionalisation 
requires only one-step from unmodified proteins and tolerates 
standard formulation buffers. The reaction is reproducible and 
proceeds in good PCC yields. Photoactivatable ArN3 dyes are 
easy to synthesize, can be crystallized, are bench stable, and are 
not susceptible to hydrolysis. Finally, the conjugation process 
is simple and user-friendly, and unlike other modification 
chemistries, requires no additional protein handling steps, such 
as pre-purification or pre-functionalization. We continue to ex-
pand on these proof-of-concept studies by developing photoac-
tivatable dyes (PhotoTags) using a range of fluorophore classes 
and different photoactive groups. 
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